Congress agreed to a sweeping package earlier last week that included a number of important healthcare provisions, including an extension of telehealth flexibilities, relief from scheduled Medicare cuts for physicians and reform for controversial pharmacy benefit managers.

As the Biden administration winds down, the US Food and Drug Administration has submitted a proposed rule that could significantly lower the amount of nicotine in tobacco products and potentially prompt more people to quit smoking.

Lindy Li discussed a Wall Street Journal report that said the president's team had insulated him during his time at the White House.

Yet, as Biden’s administration winds down, the FDA’s actions threaten to undo that commitment, putting hundreds of thousands of lives at risk. What is especially troubling is the timing.

As 2025 approaches and federal support for women's health changes, here are 25 facts about the gender health gap to help women advocate for and advance their own health.

Biden signed the stopgap measure on Saturday. With a government shutdown narrowly avoided late Friday into Saturday morning, the House and Senate sent a funding bill to President Joe Biden's desk.

This in part because Biden's FDA has been lax in enforcing penalties ... to reducing these costs and making America healthy again. Joe Grogan is a Nonresident Senior Scholar at the USC Schaeffer ...

Biden did the second-guessing as he delivered a speech at the Brookings Institution defending his economic record and challenging Trump to preserve Democratic policy ideas when he returns to the

As the Biden administration winds down ... The next regulatory step, which the FDA took Tuesday by submitting the proposal to the Office of Management and Budget, would not mean overnight change.

The FDA has been signaling its intentions to limit nicotine levels at least since 2018, during the first Trump administration. In 2022, President Joe Biden’s FDA commissioner, Dr. Robert Califf ...

The U.S. Food and Drug Administration said on Monday it had revoked the emergency use authorization for four COVID-19 treatments, including those from Eli Lilly and Regeneron .